Soleno Therapeutics (SLNO) Return on Sales (2015 - 2026)
Soleno Therapeutics' (SLNO) quarterly Return on Sales came in at 0.0% in Q1 2026, down 30.04% on a QoQ basis from 0.0% in Q4 2025.
Soleno Therapeutics (SLNO) Return on Sales (2015 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 5 years of Return on Sales data on file, last reported at 0.0% in Q1 2026.
- On a quarterly basis, Return on Sales changed N/A year-over-year to 0.0% in Q1 2026; TTM through Mar 2026 was 0.01%, a N/A change from a year earlier, with the FY2025 full-year figure at 0.0%, changed N/A from the prior year.
- Return on Sales for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
- Over the last five years, Return on Sales for SLNO reached as high as 0.0% in Q4 2025 and fell as low as 0.05% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.00% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.00% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 0.00% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Soleno Therapeutics | 874.25 Mn | 618.67 Mn | 93.41 Mn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.05% |
| Jun 30, 2017 | -9.13% |
| Mar 31, 2017 | -0.03% |
| Dec 31, 2016 | -0.01% |
| Sep 30, 2016 | -0.08% |
| Jun 30, 2016 | -5.73% |
| Mar 31, 2016 | -0.10% |
| Dec 31, 2015 | -0.09% |
| Sep 30, 2015 | -0.13% |
| Jun 30, 2015 | -0.31% |
| Mar 31, 2015 | -1.10% |